BR112015000497A2 - composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia - Google Patents

composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia

Info

Publication number
BR112015000497A2
BR112015000497A2 BR112015000497A BR112015000497A BR112015000497A2 BR 112015000497 A2 BR112015000497 A2 BR 112015000497A2 BR 112015000497 A BR112015000497 A BR 112015000497A BR 112015000497 A BR112015000497 A BR 112015000497A BR 112015000497 A2 BR112015000497 A2 BR 112015000497A2
Authority
BR
Brazil
Prior art keywords
ylethyl
pyridazin
sulfanyl
triazolo
morpholin
Prior art date
Application number
BR112015000497A
Other languages
English (en)
Inventor
Mathieu Amandine
Goulaouic Hélène
Authelin Jean-René
Peracchia Maria-Teresa
Assadourian Sylvie
Benard Tsiala
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112015000497A2 publication Critical patent/BR112015000497A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

abstract the present invention concerns an anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea and its use in the treatment of cancer. tradução do resumo resumo patente de invenção: "composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia". a presente invenção refere-se a uma composição antitumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia, e seu uso no tratamento de câncer.
BR112015000497A 2012-07-12 2013-07-11 composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia BR112015000497A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12
PCT/EP2013/064741 WO2014009500A1 (en) 2012-07-12 2013-07-11 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Publications (1)

Publication Number Publication Date
BR112015000497A2 true BR112015000497A2 (pt) 2017-06-27

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000497A BR112015000497A2 (pt) 2012-07-12 2013-07-11 composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia

Country Status (25)

Country Link
US (1) US20150119391A1 (pt)
EP (1) EP2872119A1 (pt)
JP (1) JP2015525754A (pt)
KR (1) KR20150030761A (pt)
CN (1) CN104470500A (pt)
AR (1) AR091727A1 (pt)
AU (1) AU2013288676A1 (pt)
BR (1) BR112015000497A2 (pt)
CA (1) CA2878500A1 (pt)
CL (1) CL2015000074A1 (pt)
CO (1) CO7160069A2 (pt)
CR (1) CR20150005A (pt)
EA (1) EA201590199A1 (pt)
HK (1) HK1209642A1 (pt)
IL (1) IL236662A0 (pt)
IN (1) IN2015KN00075A (pt)
MA (1) MA37753B1 (pt)
MX (1) MX2015000532A (pt)
PH (1) PH12015500060A1 (pt)
SG (1) SG11201500123XA (pt)
TN (1) TN2015000011A1 (pt)
TW (1) TW201402121A (pt)
UY (1) UY34909A (pt)
WO (1) WO2014009500A1 (pt)
ZA (1) ZA201500129B (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
NZ541658A (en) * 2003-01-14 2008-04-30 Teva Pharma Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
BRPI0908077A2 (pt) * 2008-02-28 2015-08-25 Takeda Pharmaceutical Composição farmacêutica, métodos para prevenir ou tratar doenças, e para melhorar solubilidade em água de um composto, um sal ou uma pró-droga do mesmo
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Also Published As

Publication number Publication date
TN2015000011A1 (en) 2016-06-29
ZA201500129B (en) 2015-12-23
IL236662A0 (en) 2015-02-26
JP2015525754A (ja) 2015-09-07
CR20150005A (es) 2015-04-06
EP2872119A1 (en) 2015-05-20
CL2015000074A1 (es) 2015-06-12
US20150119391A1 (en) 2015-04-30
WO2014009500A1 (en) 2014-01-16
PH12015500060A1 (en) 2015-03-02
UY34909A (es) 2013-11-29
MA37753A3 (fr) 2018-05-31
MA37753A2 (fr) 2016-06-30
CO7160069A2 (es) 2015-01-15
TW201402121A (zh) 2014-01-16
MA37753B1 (fr) 2019-04-30
AR091727A1 (es) 2015-02-25
SG11201500123XA (en) 2015-02-27
KR20150030761A (ko) 2015-03-20
EA201590199A1 (ru) 2015-05-29
AU2013288676A1 (en) 2015-02-05
HK1209642A1 (en) 2016-04-08
MX2015000532A (es) 2015-05-15
CN104470500A (zh) 2015-03-25
CA2878500A1 (en) 2014-01-16
IN2015KN00075A (pt) 2015-07-31

Similar Documents

Publication Publication Date Title
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
IN2015MN00478A (pt)
NZ711948A (en) Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
MX367897B (es) Derivados de piridazinona macrociclicos.
WO2015009726A3 (en) Medical uses of cd38 agonists
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
BR112015000497A2 (pt) composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.